Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lower drug dose may offer same benefit with fewer side effects for thyroid cancer patients

NCT ID NCT01896479

Ongoing Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a lower dose (60 mg) of the drug cabozantinib works as well as the standard higher dose (140 mg) in people with progressive, metastatic medullary thyroid cancer. The goal is to see if the lower dose can control cancer growth for a similar length of time while causing fewer side effects. About 247 participants took either the lower or higher dose daily, and researchers compared how long their cancer stayed stable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

cabozantinib (XL184)

What this could lead to

If successful, this could show that a lower dose of cabozantinib works just as well as the higher dose but with fewer side effects, improving quality of life for patients.

What could go wrong

This is a phase 4 study comparing two known doses, so it is not testing a new treatment. The lower dose may prove less effective in controlling cancer progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEDULLARY THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Medullary medullary thyroid gland carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MEDULLARY THYROID CANCER

Contacts and locations

Locations

  • Study site

    St Leonards, New South Wales, 2065, Australia

  • Study site

    Herston, Queensland, 4006, Australia

  • Study site

    Kurralta Park, South Australia, 5037, Australia

  • Study site

    Parkville, Victoria, 3050, Australia

  • Study site

    Québec, Quebec, JIH 5N4, Canada

  • Study site

    Toronto, M5G 2M9, Canada

  • Study site

    Osijek, 31000, Croatia

  • Study site

    Zagreb, 10000, Croatia

  • Study site

    Zagreb, 1000, Croatia

  • Study site

    Bordeaux, Gironde, 33076, France

  • Study site

    Angers, Maine-et-Loire, 49933, France

  • Study site

    Lyon, Rhône, 69373, France

  • Study site

    Villejuif, Val-de-Marne, 94805, France

  • Study site

    Dijon, 21079, France

  • Study site

    Paris, 75013, France

  • Study site

    Strasbourg, 67065, France

  • Study site

    Budapest, 1088, Hungary

  • Study site

    Debrecen, 4032, Hungary

  • Study site

    Jerusalem, 91120, Israel

  • Study site

    Petah Tikva, 49100, Israel

  • Study site

    Safed, 13100, Israel

  • Study site

    Catania, CT, 95124, Italy

  • Study site

    Roma, RM, 00161, Italy

  • Study site

    Siena, SI, 53100, Italy

  • Study site

    Pisa, Tuscany, 56124, Italy

  • Study site

    Milan, 20133, Italy

  • Study site

    Padua, 35138, Italy

  • Study site

    Torino, 10153, Italy

  • Study site

    Amsterdam, North Holland, 1066 CX, Netherlands

  • Study site

    Leiden, South Holland, 2333 ZA, Netherlands

  • Study site

    Groningen, 9713 GZ, Netherlands

  • Study site

    Poznan, Greater Poland Voivodeship, 60-355, Poland

  • Study site

    Gliwice, Silesian Voivodeship, 44-100, Poland

  • Study site

    Bucharest, 10825, Romania

  • Study site

    Bucharest, 11863, Romania

  • Study site

    Cluj-Napoca, 400058, Romania

  • Study site

    Timișoara, 300723, Romania

  • Study site

    Novosibirsk, 630068, Russia

  • Study site

    Obninsk, 249036, Russia

  • Study site

    Saint Petersburg, 197089, Russia

  • Study site

    Yaroslavl, 150040, Russia

  • Study site

    Goyang, Gyeonggido, 410769, South Korea

  • Study site

    Seoul, 110744, South Korea

  • Study site

    Seoul, 135-710, South Korea

  • Study site

    Barcelona, 08035, Spain

  • Study site

    Madrid, 28034, Spain

  • Study site

    Madrid, 28046, Spain

  • Study site

    Lund, Skane Ian, SE-22185, Sweden

  • Study site

    Uppsala, Uppsala Ian, 75185, Sweden